BRPI0215213C1 - peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica - Google Patents

peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica

Info

Publication number
BRPI0215213C1
BRPI0215213C1 BRPI0215213A BR0215213A BRPI0215213C1 BR PI0215213 C1 BRPI0215213 C1 BR PI0215213C1 BR PI0215213 A BRPI0215213 A BR PI0215213A BR 0215213 A BR0215213 A BR 0215213A BR PI0215213 C1 BRPI0215213 C1 BR PI0215213C1
Authority
BR
Brazil
Prior art keywords
peptides
casein kinase
phosphorylation site
binding
pharmaceutical composition
Prior art date
Application number
BRPI0215213A
Other languages
English (en)
Other versions
BR0215213A (pt
BRPI0215213B1 (pt
Inventor
Moro Soria Alejandro
Santos Savio Alicia
González Barrios Belkis
Javier González López Luis
Francisco Santiago Vispo Nelson
Reyes Acosta Osvaldo
Silva Rodríguez Ricardo
Ernesto Perea Rodríguez Silvio
Puchades Izaguirre Yaquelín
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of BR0215213A publication Critical patent/BR0215213A/pt
Publication of BRPI0215213B1 publication Critical patent/BRPI0215213B1/pt
Publication of BRPI0215213C1 publication Critical patent/BRPI0215213C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, composição farmacêutica, uso dos peptídeos, e, vetor de expressão em células de mamíferos". peptídeos úteis para o tratamento de tumores de origem epitelial e especialmente aqueles associados a tipos oncogênicos de vírus papiloma (hpv). identificação de peptídeos cuja estrutura permita o bloqueio do domínio de fosforilação por caseína quinase (ckii) mediante a interação direta com referido sítio. na presente invenção mostra-se onze peptídeos com estrutura cíclica e seqüência de aminoácidos diferente, os quais inibem o sítio de fosforilação por ckii in vitro, produzem citotoxicidade em células de carcinoma de colo uterino humano transformadas por hpv-16 (caski) e, adicionalmente, incrementam a sensibilidade de referidas células ao efeito citostático do interferon (ifn). a invenção refere-se adicionalmente ao uso de moléculas miméticas tanto de origem peptídica como de origem química.
BRPI0215213A 2001-12-20 2002-12-04 peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica BRPI0215213C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20010309A CU23225A1 (es) 2001-12-20 2001-12-20 PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU0309/01 2001-12-20
PCT/CU2002/000010 WO2003054002A1 (es) 2001-12-20 2002-12-04 Péptidos para el tratamiento del cáncer asociado al virus papiloma humano (vph) y de otros tumores epiteliales

Publications (3)

Publication Number Publication Date
BR0215213A BR0215213A (pt) 2004-12-07
BRPI0215213B1 BRPI0215213B1 (pt) 2018-09-11
BRPI0215213C1 true BRPI0215213C1 (pt) 2021-05-25

Family

ID=40091679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215213A BRPI0215213C1 (pt) 2001-12-20 2002-12-04 peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica

Country Status (33)

Country Link
US (2) US7374767B2 (pt)
EP (2) EP2383282A1 (pt)
JP (1) JP4056476B2 (pt)
KR (1) KR100642437B1 (pt)
CN (1) CN100368431C (pt)
AR (1) AR037825A1 (pt)
AT (1) ATE520704T1 (pt)
AU (1) AU2002361922B2 (pt)
BR (1) BRPI0215213C1 (pt)
CA (1) CA2471110C (pt)
CR (1) CR7361A (pt)
CU (1) CU23225A1 (pt)
DK (1) DK1491553T3 (pt)
DO (1) DOP2002000548A (pt)
ES (1) ES2371239T3 (pt)
HN (1) HN2002000377A (pt)
HR (1) HRP20040663B1 (pt)
IL (2) IL162633A0 (pt)
IS (1) IS2906B (pt)
MA (1) MA27868A1 (pt)
MX (1) MXPA04005832A (pt)
MY (1) MY133530A (pt)
NO (1) NO333259B1 (pt)
NZ (1) NZ534170A (pt)
PE (1) PE20030861A1 (pt)
PT (1) PT1491553E (pt)
RU (1) RU2290410C2 (pt)
SI (1) SI1491553T1 (pt)
TN (1) TNSN04114A1 (pt)
UA (1) UA81403C2 (pt)
UY (1) UY27602A1 (pt)
WO (1) WO2003054002A1 (pt)
ZA (1) ZA200405514B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
CN100522992C (zh) * 2007-02-12 2009-08-05 中国科学院昆明动物研究所 一种环状小肽ba
CN101641104B (zh) 2007-03-27 2013-06-05 大幸药品株式会社 感染性皮肤和粘膜疾病治疗药
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
EP2406379A4 (en) * 2009-03-13 2012-09-26 Egen Inc COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CU24766B1 (es) 2021-07-09 2025-08-13 Ct Ingenieria Genetica Biotecnologia Péptidos lineales que inhiben la fosforilación mediada por ck2
CN118370805B (zh) * 2024-04-29 2025-02-14 广州中科佰氏健康产业有限公司 一种抑菌妇科凝胶及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
CA2077322A1 (en) * 1991-09-04 1993-03-05 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
ATE235509T1 (de) * 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
AU2001238347A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Also Published As

Publication number Publication date
CR7361A (es) 2005-02-18
US7374767B2 (en) 2008-05-20
HK1068901A1 (en) 2005-05-06
AU2002361922A1 (en) 2003-07-09
CA2471110C (en) 2017-01-31
UY27602A1 (es) 2003-04-30
HN2002000377A (es) 2003-04-10
AU2002361922B2 (en) 2007-04-05
IS2906B (is) 2014-11-15
NZ534170A (en) 2006-08-31
BR0215213A (pt) 2004-12-07
KR20050002811A (ko) 2005-01-10
UA81403C2 (en) 2008-01-10
US20060233742A1 (en) 2006-10-19
CU23225A1 (es) 2007-08-30
HRP20040663B1 (hr) 2013-05-31
CN1620464A (zh) 2005-05-25
WO2003054002A1 (es) 2003-07-03
DK1491553T3 (da) 2011-12-05
ZA200405514B (en) 2005-03-30
HRP20040663A2 (en) 2005-08-31
MXPA04005832A (es) 2004-09-13
CN100368431C (zh) 2008-02-13
NO20043112L (no) 2004-07-20
RU2004122084A (ru) 2005-03-27
IL162633A (en) 2011-02-28
DOP2002000548A (es) 2003-06-30
ATE520704T1 (de) 2011-09-15
IL162633A0 (pt) 2005-11-20
SI1491553T1 (sl) 2011-12-30
PE20030861A1 (es) 2003-12-02
IS7320A (is) 2004-06-16
CA2471110A1 (en) 2003-07-03
KR100642437B1 (ko) 2006-11-06
EP2383282A1 (en) 2011-11-02
AR037825A1 (es) 2004-12-09
MY133530A (en) 2007-11-30
BRPI0215213B1 (pt) 2018-09-11
US20090005294A1 (en) 2009-01-01
JP4056476B2 (ja) 2008-03-05
EP1491553A1 (en) 2004-12-29
ES2371239T3 (es) 2011-12-28
NO333259B1 (no) 2013-04-22
RU2290410C2 (ru) 2006-12-27
MA27868A1 (fr) 2006-05-02
EP1491553B1 (en) 2011-08-17
PT1491553E (pt) 2011-11-25
TNSN04114A1 (en) 2006-06-01
US7947287B2 (en) 2011-05-24
JP2005525090A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
BRPI0215213C1 (pt) peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica
Saha et al. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention
CY1110941T1 (el) Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας
JP2006521819A (ja) 小分子、タンパク質、及び核酸の細胞内輸送
NO20053920L (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
ATE207495T1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
CN106749594B (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
BRPI0511196A (pt) polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
BR112022001866A2 (pt) Derivados de amida híbridos de anfotericina b
Ge et al. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer
WO2022094139A1 (en) Peptide inhibitors for the treatment and prevention of coronavirus infections
Chen et al. Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
Lei et al. Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1
CN108409839B (zh) 一种MDM2与p53相互作用的多肽抑制剂及其应用
US8685923B2 (en) Fibrillar albumin for use in inhibiting cancer growth
Brabant et al. A flavivirus protein M-derived peptide directly permeabilizes mitochondrial membranes, triggers cell death and reduces human tumor growth in nude mice
BR112022006862A2 (pt) Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
EP4269424A1 (en) Novel antiviral compounds and use thereof
CY1112340T1 (el) Πεπτιδια για την θεραπευτικη αγωγη καρκινου που συνδεεται με τον ιο ανθρωπινων θηλωματων (hpv) και αλλων επιθηλιακων ογκων
Pedroza-Saavedra et al. Molecular bases of human papillomavirus pathogenesis in the development of cervical cancer
AR014768A1 (es) Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparac
US11045519B2 (en) Arginine-rich polypeptide compositions and methods of using same
Singh et al. Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas
BR0107421A (pt) Processos de preparação de uma solução purificada de polipeptìdeo solúvel em solvente aquoso e de modulação do sistema imunológico de um mamìfero, polipeptìdeo recombinante, utilização de um polipeptìdeo recombinante, composição terapêutica e vacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/08/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2485 DE 21/08/2018, QUANTO AO TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.